215 related articles for article (PubMed ID: 24966701)
1. Hepatitis C in Argentina: epidemiology and treatment.
Gaite LA; Marciano S; Galdame OA; Gadano AC
Hepat Med; 2014; 6():35-43. PubMed ID: 24966701
[TBL] [Abstract][Full Text] [Related]
2. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
4. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
[TBL] [Abstract][Full Text] [Related]
6. Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.
Garnock-Jones KP
Drugs; 2012 Dec; 72(18):2431-56. PubMed ID: 23231027
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Kwo PY; Lawitz EJ; McCone J; Schiff ER; Vierling JM; Pound D; Davis MN; Galati JS; Gordon SC; Ravendhran N; Rossaro L; Anderson FH; Jacobson IM; Rubin R; Koury K; Pedicone LD; Brass CA; Chaudhri E; Albrecht JK;
Lancet; 2010 Aug; 376(9742):705-16. PubMed ID: 20692693
[TBL] [Abstract][Full Text] [Related]
8. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
9. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.
Kanda T; Nakamoto S; Nakamura M; Jiang X; Miyamura T; Wu S; Yokosuka O
J Clin Transl Hepatol; 2014 Mar; 2(1):1-6. PubMed ID: 26356295
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hepatitis B and C in children.
El-Shabrawi M; Hassanin F
Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
[TBL] [Abstract][Full Text] [Related]
12. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
[TBL] [Abstract][Full Text] [Related]
13. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
Seeff LB; Hoofnagle JH
Clin Liver Dis; 2003 Feb; 7(1):261-87. PubMed ID: 12691470
[TBL] [Abstract][Full Text] [Related]
14. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan.
Hsieh MH; Yeh ML; Su TH; Liu TW; Huang CF; Huang CI; Wang SC; Huang JF; Dai CY; Kao JH; Chuang WL; Chen PJ; Liu CJ; Yu ML
J Formos Med Assoc; 2018 Jun; 117(6):497-504. PubMed ID: 28694000
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic hepatitis C in Asia: when East meets West.
Yu ML; Chuang WL
J Gastroenterol Hepatol; 2009 Mar; 24(3):336-45. PubMed ID: 19335784
[TBL] [Abstract][Full Text] [Related]
16. A review of standard and newer treatment strategies in hepatitis C.
Tran TT
Am J Manag Care; 2012 Dec; 18(14 Suppl):S340-9. PubMed ID: 23327540
[TBL] [Abstract][Full Text] [Related]
17. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
Perry CM
Drugs; 2012 Mar; 72(5):619-41. PubMed ID: 22439668
[TBL] [Abstract][Full Text] [Related]
18. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
19. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
Saxena V; Manos MM; Yee HS; Catalli L; Wayne E; Murphy RC; Shvachko VA; Pauly MP; Chua J; Monto A; Terrault NA
Aliment Pharmacol Ther; 2014 May; 39(10):1213-24. PubMed ID: 24654657
[TBL] [Abstract][Full Text] [Related]
20. Telaprevir: changing the standard of care of chronic hepatitis C.
Rajani AK; Ravindra BK; Dkhar SA
J Postgrad Med; 2013; 59(1):42-7. PubMed ID: 23525057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
